| Name | C4X Discovery Holdings |
|---|---|
| Epic | C4XD |
| Isin | GB00BQQ2RV18 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 12.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £30.27 | Debt ratio | n/a |
| Shares in issue | 252.23 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -234.92 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -4.42 | 52-week high / low | 7.80p / 21.45p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | C4X Discovery Holdings |
|---|---|
| Address | Manchester One, 53 Portland Street, Manchester, United Kingdom, M1 3LD |
| Telephone | +44 (0)161 235 5085 |
| Website | http://www.c4xdiscovery.com |
| Director | Position |
|---|---|
| Dr Clive Dix | CEO |
| Mr Bradley Hoy | CFO |
| Mr Simon Harford | Non-Executive Director |
| Mr Alexander James Stevenson | Non-Executive Director |
| Ms Natalie Walter | Non-Executive Director |
| Mr Eva-Lotta Allan | Non-Executive Chairman |
| Ms Bhavna Hunjan | Chief Business Officer |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/07/23 | 31/07/22 | 31/07/21 |
| Intangible asssets and goodwill | 1.25 | 1.25 | 1.26 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 1.69 | 2.01 | 1.67 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.57 | 3.07 | 0.57 |
| Cash and equivalents | 4.22 | 5.08 | 17.1 |
| Other current assets and asset held for resale | 2.31 | 4.43 | 2.05 |
| Total of all assets | 8.78 | 14.58 | 21.4 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 2.16 | 2.35 | 1.86 |
| Long term liabilities | 0.09 | 0.42 | 0.25 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 2.25 | 2.78 | 2.12 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 6.53 | 11.8 | 19.29 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 4.54 | 4.32 | 4.3 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -60.6 | -49.49 | -41.34 |
| Share premium account | 58.54 | 53.35 | 53.04 |
| Total equity | 6.53 | 11.8 | 19.29 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -13.41 | -10.52 | -5.89 |
| Pre-tax profit | -13.42 | -10.53 | -5.91 |